Summary
The Miniature Schnauzer carries one of the most well-documented breed-specific metabolic predispositions in companion animal medicine. A prevalence study of 192 healthy Miniature Schnauzers found that 32.8% had serum triglyceride concentrations above the reference range, compared with just 5.3% of other breeds.¹ This idiopathic hypertriglyceridaemia, presumed to have a heritable basis, is the primary risk factor for pancreatitis in the breed: Schnauzers with a history of pancreatitis are approximately five times more likely to have hypertriglyceridaemia than age-matched controls.² The gut microbiome connects to this metabolic picture through the gut-metabolic axis. Dysbiosis impairs bile acid biotransformation, reduces short-chain fatty acid production, elevates circulating lipopolysaccharides, and contributes to systemic inflammation and hepatic lipid accumulation, all of which amplify the breed’s underlying metabolic vulnerability. Supporting the Miniature Schnauzer’s gut microbiome through daily prebiotic, probiotic, and postbiotic intervention is the most evidence-aligned nutritional strategy for this breed across its lifetime.
Introduction
The Miniature Schnauzer is a popular, spirited breed with one of the most recognisable metabolic profiles in veterinary medicine. Ask any small animal clinician which breed they most frequently encounter in pancreatitis consultations, and the Miniature Schnauzer will appear near the top of every list. Ask which breed is most predisposed to idiopathic hyperlipidaemia, and the answer is the same. These facts are not coincidental. They describe a single interconnected metabolic thread that runs through the breed from early adulthood onwards.
What has become increasingly clear is that the gut microbiome plays a meaningful role within that metabolic thread. Through the gut-metabolic axis, the bacterial populations of the gastrointestinal tract influence triglyceride metabolism, bile acid transformation, hepatic fat regulation, and the systemic inflammatory tone that ultimately determines how vulnerable a Miniature Schnauzer is to the consequences of its own lipid profile. Gut health is not a peripheral concern for this breed. It is a metabolic foundation.
This guide explains the Miniature Schnauzer gut health profile in full: the breed-specific predisposition to hypertriglyceridaemia and its association with pancreatitis, the mechanisms by which the gut microbiome modulates lipid metabolism and hepatic function, the role of bile acid dysmetabolism in amplifying metabolic risk, and the secondary gut-relevant conditions that complete the breed picture, including urolithiasis and Schnauzer comedo syndrome.
Key Takeaways
- Idiopathic hypertriglyceridaemia affects approximately one-third of healthy Miniature Schnauzers, increasing in prevalence and severity with age.
- Hypertriglyceridaemia has a presumed heritable basis and is the primary established risk factor for pancreatitis in the breed.
- The gut-metabolic axis connects gut microbiome composition to triglyceride metabolism, bile acid biotransformation, and hepatic fat regulation through several well-characterised mechanisms.
- Gut dysbiosis elevates circulating lipopolysaccharides (LPS), increasing systemic inflammatory tone and amplifying hepatic and pancreatic vulnerability.
- The Miniature Schnauzer is also predisposed to calcium oxalate and struvite urolithiasis; gut microbiome composition, specifically oxalate-degrading bacterial populations, is a relevant factor in calcium oxalate stone risk.
- Schnauzer comedo syndrome is a hereditary breed-specific skin condition that provides a minor gut-skin axis consideration in dogs presenting with concurrent inflammatory skin signs.
- Daily microbiome support through the Biotics Triad is the foundational nutritional approach for this breed throughout its life.
In This Guide
- The Gut Health Profile of the Miniature Schnauzer
- Hyperlipidaemia in the Miniature Schnauzer: A Breed-Specific Metabolic Predisposition
- The Gut-Metabolic Axis: How the Microbiome Connects to Lipid Regulation and Pancreatic Health
- Gut Dysbiosis and Metabolic Endotoxaemia: The Mechanisms That Matter
- Bile Acids, the Gut Microbiome, and Hepatic Lipid Metabolism in the Schnauzer
- Schnauzer Comedo Syndrome and the Gut-Skin Thread
- How Bonza Supports Miniature Schnauzer Gut Health
- How To Support Your Miniature Schnauzer’s Gut Health: A Practical Guide
- Safety Considerations and When to See Your Vet
- Frequently Asked Questions
- Conclusion
- Related Articles
- References
- Editorial Information
The Gut Health Profile of the Miniature Schnauzer
The Miniature Schnauzer’s gut health profile is defined by a metabolic specificity that few other breeds share. At its centre is a breed-level predisposition to lipid dysregulation that connects the gut microbiome to two of the Schnauzer’s most clinically significant health challenges: pancreatitis and liver disease.
The breed’s primary metabolic vulnerability is idiopathic hypertriglyceridaemia (iHTG), a condition in which circulating triglyceride concentrations are persistently elevated in the absence of an identifiable secondary cause. Unlike secondary hyperlipidaemia, which arises from conditions such as hypothyroidism, hyperadrenocorticism, or diabetes mellitus, the Miniature Schnauzer’s hypertriglyceridaemia occurs in otherwise healthy dogs and is presumed to have a heritable basis, though the precise genetic mechanism has not been fully characterised.¹
This metabolic predisposition interacts with the gut microbiome through multiple documented pathways. The gut microbiota influences short-chain fatty acid (SCFA) production, bile acid metabolism, intestinal barrier integrity, and the circulating level of bacterial lipopolysaccharides (LPS) that enter systemic circulation when the gut barrier is compromised. Each of these pathways has a direct bearing on how triglycerides are processed, how the liver handles fat, and how much systemic inflammation a Miniature Schnauzer carries as a baseline metabolic state.
Secondary gut health considerations, including predisposition to calcium oxalate and struvite urolithiasis and Schnauzer comedo syndrome, add further clinical texture to this picture. Neither, however, reaches the clinical significance of the lipid-microbiome-pancreas axis that defines the breed’s gut health profile.
Hyperlipidaemia in the Miniature Schnauzer: A Breed-Specific Metabolic Predisposition
Among all dog breeds, the Miniature Schnauzer stands out for the frequency and consistency with which hypertriglyceridaemia is observed, even in apparently healthy individuals. In the most frequently cited prevalence study, 32.8% of 192 healthy Miniature Schnauzers had serum triglyceride concentrations above the reference range, compared with 5.3% of healthy dogs from other breeds.¹ Both the prevalence and the severity of hypertriglyceridaemia increase with age, and some studies indicate that more than 75% of Miniature Schnauzers are affected by ten years of age.⁴
The lipoprotein pattern in affected dogs is distinctive. Miniature Schnauzers with idiopathic hypertriglyceridaemia carry increased very low-density lipoprotein (VLDL) and chylomicrons, consistent with impaired clearance or increased production of triglyceride-rich lipoproteins. Lipoprotein lipase (LPL) and hepatic lipase, both central to clearing circulating triglycerides, appear to be reduced in activity in affected dogs, contributing to the accumulation of VLDL and associated lipid fractions.⁴
The clinical consequence most frequently associated with this lipid profile is pancreatitis. Miniature Schnauzers with a history of pancreatitis are approximately five times more likely to have hypertriglyceridaemia than age-matched controls without a pancreatitis history.² A related study found a significant positive correlation between serum triglyceride concentrations and canine pancreatic lipase immunoreactivity (cPLI) concentrations across 195 Miniature Schnauzers, with dogs displaying severe hypertriglyceridaemia (above 862 mg/dL) being 4.5 times more likely to have cPLI readings consistent with pancreatitis than normotriglyceridaemic controls.³
It is important to be clear about what this association does and does not mean. Hypertriglyceridaemia is associative with pancreatitis, not a simple dietary cause. Pancreatitis in the Miniature Schnauzer is multifactorial, involving genetics, dietary fat intake, concurrent disease, and systemic inflammatory susceptibility. The gut microbiome’s role operates within this context: it modulates the metabolic and inflammatory environment that determines how vulnerable a given dog is to the downstream consequences of its lipid profile, rather than causing pancreatitis directly.
Beyond pancreatitis, elevated triglycerides in the Miniature Schnauzer are associated with higher serum liver enzyme activities, proteinuria, gallbladder mucoceles, and elevated fasting serum insulin, together describing a systemic metabolic phenotype rather than a single isolated disease relationship.⁴
The Gut-Metabolic Axis: How the Microbiome Connects to Lipid Regulation and Pancreatic Health
The gut-metabolic axis describes the bidirectional relationship between the gut microbiome and host metabolic function. For the Miniature Schnauzer, understanding this axis is not an abstract scientific exercise. It is a practical clinical framework for appreciating why gut microbiome health is a lifelong metabolic priority in this breed.
The gut microbiota regulates triglyceride metabolism through several interconnected mechanisms. SCFAs, produced by bacterial fermentation of dietary fibre, modulate hepatic lipogenesis and fat oxidation. Butyrate in particular has been shown to promote fatty acid oxidation, reduce hepatic triglyceride accumulation, and help prevent diet-induced hypertriglyceridaemia in animal models.⁷ When SCFA-producing bacterial populations decline through dysbiosis, this modulating influence is reduced. In a breed already predisposed to elevated circulating triglycerides, the loss of these gut-mediated metabolic buffers compounds the underlying heritable vulnerability.
Gut dysbiosis also impairs bile acid metabolism and permits greater translocation of LPS into systemic circulation. LPS activates inflammatory signalling in the liver and adipose tissue, promotes hepatic fat accumulation, and contributes to the low-grade systemic inflammation that elevates baseline pancreatic vulnerability.⁷ The gut microbiome further influences metabolic hormones through tryptophan metabolism: indole derivatives produced from tryptophan stimulate GLP-1 secretion from enteroendocrine L-cells, a hormone with important roles in insulin secretion, beta-cell function, and hepatic lipid regulation.⁷ When this signalling pathway is disrupted by dysbiosis, the consequences extend beyond the gut to systemic metabolic hormone function.
For the Miniature Schnauzer, whose lipid metabolism is under consistent heritable strain, a dysbiotic gut simultaneously removes multiple layers of metabolic buffering.
Gut Dysbiosis and Metabolic Endotoxaemia: The Mechanisms That Matter
Gut dysbiosis in dogs is characterised by a reduction in beneficial SCFA-producing populations, impaired bile acid biotransformation, and expansion of facultative anaerobic bacteria, particularly from the family Enterobacteriaceae.⁶ The most clinically significant consequence for the Miniature Schnauzer is metabolic endotoxaemia.
The outer membranes of Gram-negative bacteria contain LPS, which are among the most potent activators of the innate immune system. A healthy gut barrier prevents LPS from translocating from the intestinal lumen into systemic circulation. When tight junction protein expression is reduced and mucosal integrity is compromised through dysbiosis, LPS enters systemic circulation in greater quantities.⁷
Circulating LPS binds to toll-like receptor 4 (TLR4) in the liver, adipose tissue, and pancreas, activating inflammatory cytokine production. In the liver, this LPS-driven inflammation promotes hepatic fat accumulation and impairs the lipid clearance mechanisms that would otherwise help manage circulating triglycerides.⁷ In a breed whose hepatic lipid handling is already under metabolic strain from the underlying lipoprotein lipase abnormality, this additional inflammatory signal compounds the metabolic risk substantially.
At the level of the pancreas, chronic low-grade systemic inflammation associated with elevated LPS raises baseline tissue sensitivity to acute inflammatory insults. This does not mean that dysbiosis causes pancreatitis. It is a plausible mechanism by which poor gut health contributes to the inflammatory environment in which pancreatitis becomes more likely in a predisposed animal.
SCFA deficiency, the parallel consequence of dysbiosis, compounds this further. Butyrate, acetate, and propionate produced by SCFA-generating bacteria support tight junction integrity, mucosal barrier function, and anti-inflammatory signalling throughout the gut. When these populations decline, the barrier weakens, LPS translocation increases, and hepatic and systemic inflammatory tone rises, creating a self-reinforcing cycle that is especially consequential in the Miniature Schnauzer’s metabolic context.⁶
Bile Acids, the Gut Microbiome, and Hepatic Lipid Metabolism in the Schnauzer
Bile acids provide one of the most important mechanistic links between the gut microbiome and hepatic lipid regulation. The liver synthesises primary bile acids and secretes them into the gastrointestinal tract, where they facilitate the emulsification and absorption of dietary fats. In the intestine, specific bacterial species perform bile salt hydrolysis and dehydroxylation, converting primary bile acids into secondary bile acids with distinct metabolic signalling properties.⁵
This bacterial biotransformation is a regulated, health-critical process. Secondary bile acids activate nuclear receptors including the farnesoid X receptor (FXR) and the membrane receptor TGR5, which regulate hepatic lipid metabolism, triglyceride synthesis, and systemic inflammatory tone.⁵ Clostridium hiranonis (Peptacetobacter hiranonis) is among the key bile acid-metabolising species in dogs, and its reduction through antibiotic use or dysbiosis is a well-documented driver of bile acid dysmetabolism in the canine gut.⁶
When gut dysbiosis disrupts these bacterial populations, secondary bile acid production declines, primary bile acid accumulation rises, and FXR-mediated feedback on hepatic lipid synthesis is impaired. The result is a more pro-inflammatory intestinal environment and reduced regulatory constraint on hepatic triglyceride production and secretion.⁵ ⁶
For the Miniature Schnauzer, this is a clinically relevant compounding factor. Disrupted bile acid metabolism adds a hepatic metabolic burden onto a breed that already struggles with triglyceride clearance through lipoprotein lipase deficiency. The two pathways, heritable lipase impairment and microbiome-mediated bile acid dysregulation, do not operate in isolation from one another. They operate within the same hepatic metabolic environment, where the combined effect is greater than either would be alone.
Supporting gut microbiome diversity through prebiotic, probiotic, and postbiotic intervention helps maintain the bacterial populations responsible for bile acid biotransformation. This is one of the mechanistic pathways by which daily microbiome support translates into a meaningful metabolic benefit specific to this breed.
Schnauzer Comedo Syndrome and the Gut-Skin Thread
Schnauzer comedo syndrome is a hereditary, breed-specific skin condition in which multiple comedones (small, non-inflamed skin-colored bumps or papules caused by hair follicles becoming clogged with sebum (oil) and dead skin cells, manifesting as either open (blackheads) or closed (whiteheads) pores) form along the dorsal midline, typically between the shoulders and the tail. The condition involves abnormal follicular keratinisation and excess sebum production from sebaceous glands, which block the hair follicle openings and create the characteristic dorsal bumps. The genetic basis remains incompletely characterised, but the condition is considered heritable and appears to be unique to Schnauzers, with Miniature Schnauzers most commonly affected.
Schnauzer comedo syndrome is not a gut-skin axis condition in the primary mechanistic sense. Its aetiology is predominantly follicular and dermatological, with no established direct causal link to gut microbiome dysbiosis. The condition can be managed but not cured, typically through medicated shampoos, topical antiseborrheic treatments, and veterinary monitoring for secondary bacterial infections.
The gut-skin axis becomes more directly relevant in Miniature Schnauzers presenting with concurrent atopic signs, food sensitivities, or broader inflammatory skin conditions alongside the metabolic and digestive profile characteristic of the breed. In dogs where the clinical picture includes both digestive irregularity and skin inflammation, supporting the gut microbiome and gut barrier integrity contributes to the immune-inflammatory pathways that connect gut health to systemic skin outcomes, complementing any skin-specific management.
How Bonza Supports Miniature Schnauzer Gut Health
The Miniature Schnauzer’s gut health needs are defined by a specific metabolic context: a breed-level predisposition to lipid dysregulation, an elevated risk of pancreatitis, and a gut-metabolic axis that either amplifies or moderates those risks depending on the health of the gut microbiome. Daily microbiome support is the foundational priority.
Biotics is the first recommendation and the daily microbiome foundation for every Miniature Schnauzer. The Biotics Triad of prebiotics, probiotics, and postbiotics supports microbial diversity, SCFA production, gut barrier integrity, and bile acid biotransformation, the four pillars of the gut-metabolic axis most relevant to this breed. Calsporin® (Bacillus velezensis DSM 15544), the live probiotic strain within the Biotics Triad, contributes to beneficial bacterial populations and supports gut barrier function. TruPet™ provides postbiotic activity that helps maintain the mucosal environment important for LPS containment and barrier integrity. In a breed where lipid dysregulation is a lifelong metabolic pressure, daily Biotics is not an occasional supplement. It is a foundational part of the Miniature Schnauzer’s daily care.
Belly is the primary secondary recommendation for this breed. Belly supports mucosal lining integrity and gut motility, making it the most targeted secondary addition for a breed with documented digestive sensitivity, pancreatitis risk, and a gut-metabolic profile that benefits from active mucosal support. For owners managing a Miniature Schnauzer with a history of pancreatitis, chronic digestive irregularity, or any lipid-related veterinary concern, Belly alongside daily Biotics provides targeted support at both the microbiome and mucosal levels.
Block is the appropriate recommendation for Miniature Schnauzers presenting with concurrent skin symptoms, Schnauzer comedo syndrome alongside systemic inflammatory skin signs, or any atopic presentation alongside the breed’s metabolic and digestive profile. Block supports the gut-skin axis and the immune-inflammatory pathways connecting gut health to skin barrier function.
For a full explanation of the three-layer prebiotic, probiotic and postbiotic framework that underpins these recommendations, see Gut Health Supplements for Dogs: Why Probiotics Alone Are Not Enough.
How To Support Your Miniature Schnauzer’s Gut Health: A Practical Guide
Supporting your Miniature Schnauzer’s gut health requires a consistent, low-fat, microbiome-informed approach that respects the breed’s specific metabolic vulnerabilities.
- Feed a consistent, appropriate low-fat diet.
Dietary fat content is the most direct nutritional lever in managing hypertriglyceridaemia. A clinically suitable low-fat, nutritionally complete diet reduces the dietary triglyceride load and has been shown in clinical studies to reduce serum triglyceride concentrations in Miniature Schnauzers. Discuss appropriate fat levels and food choices with your vet.
- Provide daily prebiotic, probiotic, and postbiotic support.
The gut microbiome requires daily maintenance, not seasonal supplementation. Consistent Biotics supplementation helps maintain SCFA production, bile acid biotransformation, and LPS containment across the Miniature Schnauzer’s lifetime.
- Add Belly for targeted mucosal support.
For Schnauzers with a history of pancreatitis, digestive sensitivity, or gastrointestinal irregularity, Belly provides additional mucosal integrity and gut motility support alongside daily Biotics.
- Eliminate fatty treats and high-fat table scraps entirely.
Acute increases in dietary fat can precipitate pancreatic inflammation in predisposed breeds. Dietary consistency is a practical, daily risk-management step for every Miniature Schnauzer household.
- Schedule regular veterinary triglyceride and liver enzyme monitoring.
Fasting serum triglyceride and liver function testing is appropriate for this breed, particularly from five years of age onwards. Early identification of hypertriglyceridaemia permits dietary and nutritional intervention before clinical signs develop.
- Be cautious with medications known to elevate lipids.
Corticosteroids, phenobarbital, and potassium bromide can contribute to secondary hyperlipidaemia and should be used under close veterinary guidance in this breed. Always inform your vet of any existing hyperlipidaemia before initiating new medications.
- Monitor stool quality and appetite as daily indicators.
Changes in stool consistency, frequency, or appetite can signal early dysbiosis or gastrointestinal disturbance. Consistent daily observation allows owners and vets to respond before minor changes become clinical events.
Safety Considerations and When to See Your Vet
The Miniature Schnauzer’s metabolic profile warrants safety considerations that differ from most other breeds.
Any Miniature Schnauzer presenting with vomiting, abdominal pain, lethargy, or loss of appetite should be assessed by a veterinarian promptly. These signs may indicate pancreatitis, a condition for which early veterinary intervention is critical. Do not attempt to manage a suspected pancreatitis episode at home.
Dietary changes for this breed should be gradual and low-fat-conscious. Avoid any acute increase in dietary fat content, including fatty table scraps, high-fat treats, or sudden diet transitions to richer foods.
Gut health supplements, including prebiotic and probiotic products, are well-tolerated in the vast majority of dogs. If your Miniature Schnauzer has an active diagnosis of pancreatitis, is under active veterinary management for hyperlipidaemia or liver disease, or is receiving medications that may interact with gut function, discuss any supplementation with your veterinarian before starting.
Supplements and foods that are appropriate for other breeds may carry greater risk in the Miniature Schnauzer due to the breed’s specific lipid sensitivity. Introduce any new supplement gradually and monitor for digestive or systemic change.
This article is for informational purposes only and does not constitute veterinary advice. Always consult a qualified veterinarian before making changes to your dog’s diet or supplement regimen.
Frequently Asked Questions
Yes. Miniature Schnauzers are consistently overrepresented in pancreatitis cases in veterinary practice. The primary established risk factor in the breed is hypertriglyceridaemia, documented in approximately one-third of healthy Miniature Schnauzers and in more than 70% of those with a history of pancreatitis.²
Idiopathic hypertriglyceridaemia in the breed is presumed to have a heritable basis, likely involving impaired clearance of triglyceride-rich lipoproteins through reduced lipoprotein lipase activity. The precise genetic mechanism has not been fully identified. Secondary causes, including hypothyroidism, hyperadrenocorticism, and diabetes mellitus, must be excluded before an idiopathic diagnosis is made.
No. Direct clinical study in Miniature Schnauzers has linked gut microbiome composition to serum triglyceride concentrations. The relationship is established through the documented mechanisms of the gut-metabolic axis: SCFA production, bile acid biotransformation, LPS translocation, and hepatic fat regulation all connect gut microbiome health to metabolic outcomes that are particularly significant in this breed.
Yes. Miniature Schnauzers have a documented predisposition to both calcium oxalate and struvite urolithiasis. Calcium oxalate stone formation in dogs has been linked to altered gut microbiome composition, specifically reduced populations of oxalate-degrading bacteria such as Oxalobacter formigenes.⁹
A low-fat diet is the primary dietary intervention for idiopathic hypertriglyceridaemia in this breed and has been shown to reduce serum triglyceride concentrations in clinical studies. Dietary management supports, but does not replace, regular veterinary monitoring and guidance.
No. Schnauzer comedo syndrome is a hereditary follicular and dermatological condition involving abnormal keratinisation and sebum accumulation. Its aetiology is not gut-driven. However, dogs presenting with concurrent inflammatory skin signs alongside the breed’s typical metabolic and digestive profile may benefit from gut barrier and microbiome support as part of a broader management approach.
Hypertriglyceridaemia becomes more prevalent and more severe with age, increasing markedly from middle age onwards. Proactive microbiome support from adulthood, rather than waiting for clinical signs to emerge, is the most practical approach for owners of this breed.
Conclusion
The Miniature Schnauzer presents one of the clearest examples in companion animal medicine of why gut health cannot be considered separately from systemic metabolism. The breed’s idiopathic hypertriglyceridaemia is not simply a lipid measurement problem. It is a metabolic state with documented associations to pancreatitis, liver enzyme elevation, gallbladder disease, and proteinuria, all of which are modulated by the inflammatory and metabolic signalling environment that the gut microbiome helps to maintain or disrupt.
The gut-metabolic axis offers a coherent, evidence-based framework for understanding why a well-functioning gut microbiome is specifically and urgently relevant to this breed. SCFA production buffers hepatic lipogenesis. Bile acid biotransformation regulates fat absorption signalling and FXR-mediated feedback on triglyceride synthesis. LPS containment reduces the systemic inflammatory baseline that amplifies pancreatic vulnerability. These are not speculative connections. They are documented mechanisms operating through the same biological pathways that define the Miniature Schnauzer’s clinical risk profile.
For owners, the practical implication is direct: the Miniature Schnauzer needs daily microbiome support, a consistent low-fat diet, and regular veterinary monitoring as a lifelong standard of care, not as a response to symptoms. Building the gut health foundation early and maintaining it consistently is the most evidence-aligned approach to managing the metabolic vulnerabilities this exceptional breed carries.
Related Articles
- The Dog Gut Microbiome: Vital Key to Dog Health
- The Gut-Metabolic Axis in Dogs
- The Gut-Immune Axis in Dogs: How Gut Health Supports Immune Health
- Best Probiotics for Dogs: Canine Nutritionist’s Guide to Real Gut Impact
- Best Prebiotics for Dogs: Canine Nutritionist’s Complete Guide
- Gut Health Supplements for Dogs: Why Probiotics Alone Are Not Enough
- Gut Dysbiosis in Dogs: Causes, Symptoms & How to Restore Balance
References
- Xenoulis PG, Suchodolski JS, Levinski MD, Steiner JM. Investigation of hypertriglyceridemia in healthy Miniature Schnauzers. J Vet Intern Med. 2007;21(6):1224-30. doi: 10.1892/07-051.1. PMID: 18196730.
- Xenoulis PG, Levinski MD, Suchodolski JS, Steiner JM. Serum triglyceride concentrations in Miniature Schnauzers with and without a history of probable pancreatitis. J Vet Intern Med. 2011;25(1):20-5. doi: 10.1111/j.1939-1676.2010.0644.x. PMID: 21143300.
- Xenoulis PG, Suchodolski JS, Ruaux CG, Steiner JM. Association between serum triglyceride and canine pancreatic lipase immunoreactivity concentrations in miniature schnauzers. J Am Anim Hosp Assoc. 2010;46(4):229-34. doi: 10.5326/0460229. PMID: 20610694.
- Furrow E, Jaeger JQ, Parker VJ, Hinchcliff KW, Johnson SE, Murdoch SJ, de Boer IH, Sherding RG, Brunzell JD. Proteinuria and lipoprotein lipase activity in Miniature Schnauzer dogs with and without hypertriglyceridemia. Vet J. 2016;212:83-9. doi: 10.1016/j.tvjl.2016.04.009. PMID: 27256031. PMC: PMC4893197.
- Rowe JC, Winston JA. Collaborative Metabolism: Gut Microbes Play a Key Role in Canine and Feline Bile Acid Metabolism. Vet Sci. 2024;11(2):94. doi: 10.3390/vetsci11020094. PMID: 38393112. PMC: PMC10892723.
- Pilla R, Suchodolski JS. The Role of the Canine Gut Microbiome and Metabolome in Health and Gastrointestinal Disease. Front Vet Sci. 2020;6:498. doi: 10.3389/fvets.2019.00498. PMID: 31993469. PMC: PMC6971114.
- Li K, Xiao X, Li Y, Lu S, Zi J, Sun X, Xu J, Liu HY, Li X, Song T, Cai D. Insights into the interplay between gut microbiota and lipid metabolism in the obesity management of canines and felines. J Anim Sci Biotechnol. 2024 Aug 8;15(1):114. doi: 10.1186/s40104-024-01073-w. PMID: 39118186; PMCID: PMC11308499.
- Coffey EL, Gomez AM, Burton EN, Granick JL, Lulich JP, Furrow E. Characterization of the urogenital microbiome in Miniature Schnauzers with and without calcium oxalate urolithiasis. J Vet Intern Med. 2022;36(4):1341-1352. doi: 10.1111/jvim.16482. PMID: 35796316. PMC: PMC9308445.
- Gnanandarajah JS, Abrahante JE, Lulich JP, Murtaugh MP. Presence of Oxalobacter formigenes in the intestinal tract is associated with the absence of calcium oxalate urolith formation in dogs. Urol Res. 2012;40(5):467-73. doi: 10.1007/s00240-011-0451-1. PMID: 22223029.
- Gnanandarajah JS, Johnson TJ, Kim HB, Abrahante JE, Lulich JP, Murtaugh MP. Comparative faecal microbiota of dogs with and without calcium oxalate stones. J Appl Microbiol. 2012;113(4):745-56. doi: 10.1111/j.1365-2672.2012.05390.x. PMID: 22788835.
Editorial Information
| Field | Detail |
|---|---|
| Published | March 2026 |
| Last Updated | March 2026 |
| Reviewed by | Veterinary Advisory Board |
| Next Review | March 2027 |
| Author | Glendon Lloyd, Dip. Canine Nutrition (Dist.), Dip. Dog Nutrigenomics (Dist.), Founder, Bonza |
| Disclaimer | This article is for informational purposes only and does not constitute veterinary advice. Always consult a qualified veterinarian before making changes to your dog’s diet or supplement regimen. |